{"id":16774,"date":"2017-09-13T13:03:33","date_gmt":"2017-09-13T11:03:33","guid":{"rendered":"http:\/\/www.veeva.com\/eu\/?post_type=resources&p=16774"},"modified":"2026-08-21T16:17:13","modified_gmt":"2026-08-21T14:17:13","slug":"veeva-vault-etmf-helps-cancer-research-uk-improve-clinical-trial-efficiency-and-compliance","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/veeva-vault-etmf-helps-cancer-research-uk-improve-clinical-trial-efficiency-and-compliance\/","title":{"rendered":"Veeva eTMF Helps Cancer Research UK Improve Clinical Trial Efficiency and Compliance"},"content":{"rendered":"

<\/p>\n

Leading charity modernizes trial operations to develop new cancer treatments faster<\/p>\n

<\/em><\/p>\n

BARCELONA, Spain \u2014 13 September 2017 \u2014 <\/strong> Veeva Systems<\/a> (NYSE: VEEV) announced today that Cancer Research UK selected Veeva eTMF<\/a> to modernize its clinical trial processes. The organization currently sponsors and manages approximately 25 early phase oncology trials through its Centre for Drug Development. By improving regulatory compliance and increasing efficiency through active trial master file (TMF) management, Cancer Research UK aims to optimize development of new treatments for patients with cancer. <\/p>\n

\u201cOur mission is to beat cancer sooner,\u201d said Nigel Blackburn, director of drug development at Cancer Research UK. \u201cVeeva eTMF helps us maximize clinical trial efficiency and strengthen our commercial partnerships so we can accelerate the delivery of the next generation of treatments to the patients that need them.\u201d <\/p>\n

Cancer Research UK\u2019s vision is to accelerate research so that three in four patients survive cancer by 2034. Regulatory-directed drug development is key to meeting this objective. As it continued to evaluate the effectiveness of its clinical operations, Cancer Research UK identified the opportunity to increase efficiency and quality in its management of TMF documentation and processes. <\/p>\n

The Cancer Research UK Centre for Drug Development was previously using paper documents in a passive TMF operating model. Veeva eTMF enables Cancer Research UK to manage all TMF processes and documents in one system, in real time, as they are executed. This active TMF operating model maintains the organization\u2019s TMF in a constant state of inspection readiness.
\n\u201cRoutine inspection preparation used to take as long as 12 days and archiving documentation took 40 days. Veeva eTMF will allow us to complete these tasks much faster,\u201d said Stephen Nabarro, head of clinical operations and data management at Cancer Research UK. \u201cThis allows our team to efficiently manage more trials, ultimately providing more early phase treatment options for people with cancer.\u201d <\/p>\n

Veeva eTMF is a part of the Veeva Clinical Platform<\/a>, the industry’s first cloud platform to unify clinical data management and operations. By combining eTMF with applications for EDC, eSource, CTMS, study start-up, and site document exchange built on the Veeva Vault Platform, organizations can eliminate system silos and streamline end-to-end clinical trial processes. <\/p>\n

The Cancer Research UK Centre for Drug Development is celebrating 25 years of innovation and partnering with industry and academia to turn research ideas into novel therapies. The Centre\u2019s current development portfolio includes 11 small molecule agents and 13 biologicals. It has a track record of involvement in the development of six marketed drugs to date, including, most recently, rucaparib (Clovis Oncology) for the treatment of ovarian cancer. <\/p>\n

Additional Information<\/strong>
\nFor more on Veeva eTMF, visit: veeva.com\/etmf<\/a>
\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @Veeva_EU on Twitter: twitter.com\/veeva_eu <\/a>
\nLike Veeva on Facebook: facebook.com\/veevasystems<\/a><\/p>\n

About Veeva Systems<\/strong>
\nVeeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 550 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com\/eu<\/a>. <\/p>\n

Forward-looking Statements<\/strong>
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d in the company\u2019s filing on Form 10-Q for the period ended April 30, 2017. This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.<\/p>\n

###<\/p>\n

Contact:<\/strong>
\nSue Glanville \/ Cate Bonthuys
\nVeeva Systems Inc.
\nsue@catalystcomms.co.uk<\/a> \/ cate@catalystcomms.co.uk<\/a>
\n+44 (0) 7715 817589 \/ +44 (0) 7746 546773<\/p>\n","protected":false},"excerpt":{"rendered":"

Leading charity modernizes trial operations to develop new cancer treatments faster.<\/p>\n","protected":false},"featured_media":16960,"parent":0,"template":"","class_list":["post-16774","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-area-20-clinical-operations","resource-product-20-etmf","resource-type-news-press-release"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t